Physician profile
Chaouki K Khoury
NPI 1831223049
$978,322.84
in general payments reported to CMS, 2019-2025
70 companies · $250K in 2025
The $250K reported for 2025 was more than what 99% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,883 · 2020: $28K · 2021: $116K · 2022: $204K · 2023: $197K · 2024: $181K · 2025: $250K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $313K · Honoraria: $127K · Travel and Lodging: $87K · Consulting Fee: $78K · Food and Beverage: $23K · Education: $0.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $313,480.00 |
| Honoraria | $126,731.75 |
| Travel and Lodging | $86,538.12 |
| Consulting Fee | $78,183.25 |
| Food and Beverage | $22,535.63 |
| Education | $0.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537,709.84 | 2021-2025 | |
| Lundbeck LLC | $244,105.96 | 2020-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $60,547.27 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $31,778.95 | 2022 | |
| Impel Pharmaceuticals INC. | $27,462.73 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $23,764.74 | 2023-2025 | Symbravo, Auvelity, Sunosi |
| Allergan, INC. | $19,086.84 | 2019-2022 | |
| Pfizer INC. | $6,169.48 | 2019-2025 | |
| Impel Pharmaceuticals LLC | $4,871.29 | 2024-2025 | Trudhesa, Trudhesa |
| Upsher-Smith Laboratories LLC | $3,426.33 | 2019-2023 | |
| Bausch Health US, LLC | $2,183.83 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $1,935.19 | 2019-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Teva Pharmaceuticals USA, INC. | $1,299.59 | 2019-2025 | Ajovy, Austedo Xr |
| H. Lundbeck A S | $1,200.00 | 2024 | Vyepti |
| Ucb, INC. | $1,156.72 | 2019-2025 | Briviact, Fintepla |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,117.04 | 2019-2024 | Emgality, Reyvow |
| Sunovion Pharmaceuticals INC. | $930.85 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $623.93 | 2021-2025 | Epidiolex |
| Eisai INC. | $615.92 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $593.20 | 2019-2025 | Dysport |
| Neurelis, INC. | $530.25 | 2020-2025 | Valtoco |
| Amgen INC. | $479.79 | 2019-2023 | Aimovig |
| Azurity Pharmaceuticals, INC. | $443.68 | 2024-2025 | Zonisade, Horizant |
| Corium, LLC | $422.81 | 2021-2024 | Azstarys |
| Greenwich Biosciences, INC. | $421.54 | 2020-2021 | |
| Sk Life Science, INC. | $364.51 | 2020-2025 | |
| Catalyst Pharmaceuticals, INC. | $354.45 | 2023-2025 | Fycompa |
| Neos Therapeutics, Lp | $347.62 | 2020-2024 | Adzenys Xr-Odt |
| Merz Pharmaceuticals, LLC | $344.31 | 2022-2025 | Xeomin, Inbrija |
| Sumitomo Pharma America, INC. | $322.93 | 2023-2024 | Aptiom |
| Livanova USA, INC. | $291.89 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ironshore Pharmaceuticals INC. | $258.11 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $234.61 | 2020-2025 | Dyanavel Xr |
| Biocodex, INC. | $226.50 | 2019-2024 | Diacomit |
| Medtronic, INC. | $208.02 | 2022-2024 | Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $195.43 | 2019-2023 | Lyvispah |
| Tonix Medicines, INC. | $189.08 | 2024-2025 | Zembrace Symtouch |
| Biogen, INC. | $180.94 | 2019-2023 | Tysabri |
| Inspire Medical Systems, INC. | $163.67 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $152.78 | 2023-2024 | Rexulti |
| Promius Pharma LLC | $149.48 | 2019 | |
| Collegium Pharmaceutical, INC. | $136.60 | 2022-2025 | Jornay Pm |
| Nevro Corp. | $129.50 | 2022 | |
| Aquestive Therapeutics, INC. | $126.96 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $112.80 | 2019-2025 | Strensiq |
| Takeda Pharmaceuticals U.S.A., INC. | $100.01 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $79.68 | 2023-2025 | Ztlido |
| Janssen Pharmaceuticals, INC | $73.89 | 2024-2025 | Spravato |
| Acadia Pharmaceuticals INC | $66.36 | 2025 | Daybue |
| Aprecia Pharmaceuticals, LLC | $62.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.27 | 2019 | |
| Currax Pharmaceuticals LLC | $51.50 | 2020-2021 | |
| Adlon Therapeutics L.P. | $49.30 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.92 | 2024 | Caplyta |
| Immedica Pharma US, INC. | $42.66 | 2024-2025 | Ztalmy |
| Biomarin Pharmaceutical INC. | $39.72 | 2019-2021 | |
| Genzyme Corporation | $37.06 | 2019-2022 | |
| Zogenix INC. | $32.01 | 2020 | |
| Adamas Pharmaceuticals, INC. | $31.22 | 2019 | |
| Otter Pharmaceuticals, LLC | $25.36 | 2025 | Sympazan |
| Noven Therapeutics, LLC | $23.74 | 2023 | Xelstrym |
| Nobelpharma America, LLC | $20.62 | 2024 | |
| Travere Therapeutics, INC. | $19.49 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.60 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.21 | 2019 | |
| Merz North America, INC. | $14.70 | 2020 | |
| Assertio Therapeutics, INC. | $13.23 | 2020 | |
| Grifols USA, LLC | $13.22 | 2019 | |
| Aucta Pharmaceuticals, INC. | $12.75 | 2024-2025 | Motpoly Xr |
| Arbor Pharmaceuticals, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaouki Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.